Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.

Ueda, Munetaka; Tanimoto, Tetsuya; Murayama, Anju; Ozaki, Akihiko; Kami, Masahiro

Ueda, Munetaka; Tanimoto, Tetsuya; Murayama, Anju; Ozaki, Akihiko; Kami, Masahiro.

Ueda M; Japanese Red Cross Medical Center, Tokyo, Japan.
Tanimoto T; Navitas Clinic Kawasaki, Kawasaki, Japan.
Murayama A; Medical Governance Research Institute, Tokyo, Japan.
Ozaki A; Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan.
Kami M; Medical Governance Research Institute, Tokyo, Japan.

Clin Pharmacol Ther ; 111(3): 545-547, 2022 03.

Article in English | MEDLINE | ID: covidwho-1196371

Subject(s)

Amides; Antiviral Agents; Drug Approval; Pyrazines; Adenosine Monophosphate/analogs & derivatives; Adenosine Monophosphate/therapeutic use; Alanine/analogs & derivatives; Alanine/therapeutic use; Amides/therapeutic use; Antiviral Agents/therapeutic use; COVID-19/epidemiology; Clinical Trials, Phase III as Topic; Dexamethasone/therapeutic use; Double-Blind Method; Drug Approval/legislation & jurisprudence; Drug Approval/methods; Humans; Japan; Pyrazines/therapeutic use; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Drug Approval / Amides Type of study: Case report / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Pharmacol Ther Year: 2022 Document Type: Article Affiliation country: Cpt.2251

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google